natgillin/translations-raw huggingface dataset:
(+) The European Food Safety Authority identified some information on analytical methods,metabolism and the analytical method used in the residue trials as unavailable.
Za popoln seznam proizvodov rastlinskega in živalskega izvora, za katere veljajo MRL, se je treba sklicevati na Prilogo I.
(+) The European Food Safety Authority identified some information on analytical methods and the analytical method used in the residue trials as unavailable.
V skladu z Uredbo Komisije (EU) št. 823/2012 [11] je veljavnost registracije oksadiargila potekla 31. marca 2014.
(+) The European Food Safety Authority identified some information on storage stability and metabolism as unavailable.
Vse obstoječe registracije fitofarmacevtskih sredstev, ki vsebujejo aktivno snov oksadiargil, so bile preklicane in obdobja odloga se iztečejo najpozneje 30. septembra 2015.
Methoxyfenozide (F)
To ne bi smelo veljati za tiste MRL, ki ustrezajo CXL na podlagi uporabe v tretjih državah, kadar so navedene CXL sprejemljive z vidika varnosti potrošnikov.
(+) The European Food Safety Authority identified some information on analytical methods as unavailable.
Poleg tega to ne bi smelo veljati v primerih, ko so MRL natančno določene kot uvozne tolerance.
Tribenuron-methyl
Uporablja se od 21. januarja 2016.
Groups and examples of individual products to which the MRLs apply [4]
Točka (1)(c) in točka (3) Priloge pa se uporabljata od 1. oktobra 2015.
Following an application from Biocodex, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006 and including a request for protection of proprietary data, the Authority was required to deliver an opinion on a health claim related to the effect of citrulline-malate and faster recovery from muscle fatigue after exercise (Question No EFSA-Q-2013-00659 [2]).
Družba Biocodex je v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 vložila vlogo, vključno z zahtevo za zakonsko zaščito podatkov, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z učinkom citrulin malata na hitrejše okrevanje pri mišični utrujenosti po telesni dejavnosti (vprašanje št.
The claim proposed by the applicant was worded as follows: ‘Maintenance of ATP levels through reduction of lactates in excess for an improved recovery from muscle fatigue’.
EFSA-Q-2013-00659 [2]).
On 5 May 2014, the Commission and the Member States received the scientific opinion from the Authority, which concluded that a health claim on citrulline-malate and faster recovery from muscle fatigue after exercise pursuant to Article 13(5) of Regulation (EC) No 1924/2006 had already been assessed by the Authority with an unfavourable outcome (Question No EFSA-Q-2011-00931 [3]).
Vložnik je predlagal naslednjo trditev: „Ohranjanje ravni ATP z zmanjšanjem presežka laktatov za boljše okrevanje pri mišični utrujenosti.“
The additional information submitted by the applicant, in the context of Question No EFSA-Q-2013-00659, did not provide evidence that could be used for the scientific substantiation of the claim.
Komisija in države članice so 5. maja 2014 prejele znanstveno mnenje Agencije, ki je ugotovila, da je Agencija zdravstveno trditev o učinku citrulin malata na hitrejše okrevanje pri mišični utrujenosti po telesni dejavnosti v skladu s členom 13(5) Uredba (ES) št. 1924/2006 že ocenila z negativnim izidom (vprašanje št.
Accordingly, as the claim does not comply with the requirements of Regulation (EC) No 1924/2006, it should not be authorised.
EFSA-Q-2011-00931 [3]).
Following an application from Comvita New Zealand Limited, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006 and including a request for protection of proprietary data, the Authority was required to deliver an opinion on a health claim related to the effect of olive (Olea europaea L.) leaf water extract and increase in glucose tolerance (Question No EFSA-Q-2013-00783 [4]).
Dodatne informacije, ki jih je vložnik predložil v okviru vprašanja št.
The claim proposed by the applicant was worded as follows: ‘Daily intake of supplemental olive leaf extract polyphenols contributes to the reduction of the blood glucose rise after meals’.
EFSA-Q-2013-00659, niso zagotovile dokazov, ki bi se lahko uporabili pri znanstveni utemeljitvi trditve.
On 5 May 2014, the Commission and the Member States received the scientific opinion from the Authority, which concluded that on the basis of the data presented, the scientific evidence is insufficient to establish a cause and effect relationship between the consumption of olive leaf water extract and increase in glucose tolerance.
Ker zdravstvena trditev ne izpolnjuje zahtev iz Uredbe (ES) št. 1924/2006, se ne bi smela odobriti.
Following an application from Naturex SA, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006 and including a request for protection of proprietary data, the Authority was required to deliver an opinion on a health claim related to the effect of Pacran® and defence against bacterial pathogens in the lower urinary tract (Question No EFSA-Q-2013-00889 [5]).
Družba Comvita New Zealand Limited je v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 vložila vlogo, vključno z zahtevo za zakonsko zaščito podatkov, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z učinkom vodnega izvlečka iz oljčnih listov (Olea europaea L.) na povečanje tolerance na glukozo (vprašanje št.
The claim proposed by the applicant was worded as follows: ‘Pacran® helps to inhibit the adhesion of P-fimbriated E. coli to the urinary tract cells’.
EFSA-Q-2013-00783 [4]).
On 5 May 2014, the Commission and the Member States received the scientific opinion from the Authority, which concluded that on the basis of the data presented, a cause and effect relationship had not been established between the consumption of Pacran® and defence against bacterial pathogens in the lower urinary tract.
Vložnik je predlagal naslednjo trditev: „Dnevni vnos dodatnih polifenolov v izvlečku iz oljčnih listov prispeva k zmanjšanju dviga glukoze v krvi po jedi.“
Following an application from PiLeJe, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006 and including a request for protection of proprietary data, the Authority was required to deliver an opinion on a health claim related to the effect of a combination of Bifidobacterium longum LA 101, Lactobacillus helveticus LA 102, Lactococcus lactis LA 103 and Streptococcus thermophilus LA 104 and reducing intestinal discomfort (Question No EFSA-Q-2013-00892 [6]).
Komisija in države članice so 5. maja 2014 prejele znanstveno mnenje Agencije, ki je na podlagi predloženih podatkov ugotovila, da znanstveni dokazi ne zadoščajo za vzpostavitev vzročno-posledične povezave med uživanjem vodnega izvlečka iz oljčnih listov in povečanjem tolerance na glukozo.
The claim proposed by the applicant was worded, inter alia, as follows: ‘improves intestinal comfort’.
Družba Naturex SA je v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 vložila vlogo, vključno z zahtevo za zakonsko zaščito podatkov, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z učinkom proizvoda Pacran® na obrambo proti bakterijskim patogenom v spodnjem urinarnem traktu (vprašanje št.
On 5 May 2014, the Commission and the Member States received the scientific opinion from the Authority, which concluded that on the basis of the data presented, a cause and effect relationship had not been established between the consumption of a combination of Bifidobacterium longum LA 101, Lactobacillus helveticus LA 102, Lactococcus lactis LA 103 and Streptococcus thermophilus LA 104 and reducing gastro-intestinal discomfort.
EFSA-Q-2013-00889 [5]).
Following an application from PiLeJe, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006 and including a request for protection of proprietary data, the Authority was required to deliver an opinion on a health claim related to the effect of a combination of Bifidobacterium longum LA 101, Lactobacillus helveticus LA 102, Lactococcus lactis LA 103 and Streptococcus thermophilus LA 104 and improvement of bowel function by increasing stool frequency (Question No EFSA-Q-2013-00893 [7]).
Vložnik je predlagal naslednjo trditev: „Pacran® pripomore k inhibiciji adhezije bakterij E. coli s fimbrijami P na celice urinarnega trakta.“
The claim proposed by the applicant was worded, inter alia, as follows: ‘regulates your (intestinal) transit’.
Komisija in države članice so 5. maja 2014 prejele znanstveno mnenje Agencije, ki je na podlagi predloženih podatkov ugotovila, da vzročno-posledična povezava med uživanjem proizvoda Pacran® in obrambo proti bakterijskim patogenom v spodnjem urinarnem traktu ni utemeljena.
On 5 May 2014, the Commission and the Member States received the scientific opinion from the Authority, which concluded that on the basis of the data presented, a cause and effect relationship had not been established between the consumption of a combination of Bifidobacterium longum LA 101, Lactobacillus helveticus LA 102, Lactococcus lactis LA 103 and Streptococcus thermophilus LA 104 and improvement of bowel function by increasing stool frequency.
Družba PiLeJe je v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 vložila vlogo, vključno z zahtevo za zakonsko zaščito podatkov, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z učinkom kombinacije bakterij Bifidobacterium longum LA 101, Lactobacillus helveticus LA 102, Lactococcus lactis LA 103 in Streptococcus thermophilus LA 104 na zmanjšanje črevesnega nelagodja (vprašanje št.
Accordingly, as the claim does not comply with the requirements of Regulation (EC) No 1924/2006, it should not be authorised.
EFSA-Q- 2013-00892 [6]).
Following an application from DoubleGood AB, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006 and including a request for protection of proprietary data, the Authority was required to deliver an opinion on a health claim related to the effect of a combination of L-threonine, L-valine, L-leucine, L-isoleucine, L-lysine plus chromium picolinate and reduction of post-prandial glycaemic responses (Question No EFSA-Q-2013-00756 [8]).
Vložnik je med drugim predlagal naslednjo trditev: „Izboljša občutek v črevesju“.
The claim proposed by the applicant was worded as follows: ‘Contributes to the reduction of the blood glucose rise when consumed together with a carbohydrate rich meal’.
Komisija in države članice so 5. maja 2014 prejele znanstveno mnenje Agencije, ki je na podlagi predloženih podatkov ugotovila, da vzročno-posledična povezava med uživanjem kombinacije bakterij Bifidobacterium longum LA 101, Lactobacillus helveticus LA 102, Lactococcus lactis LA 103 in Streptococcus thermophilus LA 104 in zmanjšanjem črevesnega nelagodja ni utemeljena.
On 16 July 2014, the Commission and the Member States received the scientific opinion from the Authority, in which it was stated that the applicant did not provide any evidence that a reduction in post-prandial blood glucose responses achieved by an increase in insulin secretion is a beneficial physiological effect.
Družba PiLeJe je v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 vložila vlogo, vključno z zahtevo za zakonsko zaščito podatkov, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z učinkom kombinacije bakterij Bifidobacterium longum LA 101, Lactobacillus helveticus LA 102, Lactococcus lactis LA 103 in Streptococcus thermophilus LA 104 na izboljšanje delovanja črevesja s pogostejšim odvajanjem (vprašanje št.
Consequently, the Authority concluded that, on the basis of the data presented, a cause and effect relationship had not been established between the consumption of the food, a combination of L-threonine, L-valine, L-leucine, L-isoleucine, L-lysine plus chromium picolinate, which is the subject of the health claim, and a beneficial physiological effect.
EFSA-Q- 2013-00893 [7]).
Following an application from DSM Nutritional Products and Kemin Foods, submitted pursuant to Article 13(5) of Regulation (EC) No 1924/2006 and including a request for protection of proprietary data, the Authority was required to deliver an opinion on a health claim related to the effect of a combination of lutein and zeaxanthin and improved vision under bright light conditions (Question No EFSA-Q-2013-00875 [9]).
Vložnik je med drugim predlagal naslednjo trditev: „Ureja vaše prehajanje črevesne vsebine“.
The claim proposed by the applicants was worded as follows: ‘Lutein together with zeaxanthin helps maintain clarity and contrast of sight in bright light conditions’.
Komisija in države članice so 5. maja 2014 prejele znanstveno mnenje Agencije, ki je na podlagi predloženih podatkov ugotovila, da vzročno-posledična povezava med uživanjem kombinacije bakterij Bifidobacterium longum LA 101, Lactobacillus helveticus LA 102, Lactococcus lactis LA 103 in Streptococcus thermophilus LA 104 in izboljšanjem delovanja črevesja s pogostejšim odvajanjem ni utemeljena.
On 16 July 2014, the Commission and the Member States received the scientific opinion from the Authority, which concluded that on the basis of the data presented, a cause and effect relationship had not been established between the consumption of a combination of lutein and zeaxanthin and improved vision under bright light conditions.
Ker zdravstvena trditev ne izpolnjuje zahtev iz Uredbe (ES) št. 1924/2006, se ne bi smela odobriti.
The measures provided for in this Regulation are in accordance with the opinion of the Standing Committee on Plants, Animals, Food and Feed,
Družba DoubleGood AB je v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 vložila vlogo, vključno z zahtevo za zakonsko zaščito podatkov, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z učinkom kombinacije L-treonina, L-valina, L-levcina, L-izolevcina, L-lizina in kromovega pikolinata na zmanjšanje postprandialnega glikemičnega odziva (vprašanje št.
HAS ADOPTED THIS REGULATION:
EFSA-Q-2013-00756 [8]).
Article 1
Vložnik je predlagal naslednjo trditev: „Prispeva k manjšemu porastu glukoze v krvi, kadar se zaužije skupaj z obrokom, bogatim z ogljikovimi hidrati.“
The health claims listed in the Annex to this Regulation shall not be included in the Union list of permitted claims as provided for in Article 13(3) of Regulation (EC) No 1924/2006.
Komisija in države članice so 16. julija 2014 prejele znanstveno mnenje Agencije, v katerem je navedeno, da vložnik ni predložil nobenih dokazov, da je zmanjšanje postprandialnega odziva v ravni glukoze v krvi, ki se doseže s povečanjem izločanja inzulina, pozitiven fiziološki učinek.
Article 2
Zato je Agencija na podlagi predloženih podatkov sklenila, da vzročno-posledična povezava med uživanjem živil s kombinacijo L-treonina, L-valina, L-levcina, L-izolevcina, L-lizina in kromovega pikolinata, na katere se nanaša zdravstvena trditev, ter pozitivnim fiziološkim učinkom ni utemeljena.
This Regulation shall enter into force on the twentieth day following that of its publication in the Official Journal of the European Union.
Družba DSM Nutritional Products and Kemin Foods je v skladu s členom 13(5) Uredbe (ES) št. 1924/2006 vložila vlogo, vključno z zahtevo za zakonsko zaščito podatkov, Agencija pa je morala pripraviti mnenje o zdravstveni trditvi v zvezi z učinkom kombinacije luteina in zeaksantina na boljši vid pri močni svetlobi (vprašanje št.
This Regulation shall be binding in its entirety and directly applicable in all Member States.
EFSA-Q-2013-00875 [9]).
Done at Brussels, 30 June 2015.
Vložniki so predlagali naslednjo trditev: „Lutein skupaj z zeaksantinom pomaga ohranjati jasen vid, zmožen prepoznave kontrastov, pri močni svetlobi.“
For the Commission
Komisija in države članice so 16. julija 2014 prejele znanstveno mnenje Agencije, ki je na podlagi predloženih podatkov ugotovila, da vzročno-posledična povezava med uživanjem kombinacije luteina in zeaksantina ter boljši vid pri močni svetlobi ni utemeljena.
The President
Ukrepi iz te uredbe so v skladu z mnenjem Stalnega odbora za rastline, živali, hrano in krmo –
OJ L 404, 30.12.2006, p. 9.
SPREJELA NASLEDNJO UREDBO:
ANNEX
UL L 404, 30.12.2006, str. 9.
Rejected health claims
PRILOGA
Application — Relevant provisions of Regulation (EC) No 1924/2006
Zavrnjene zdravstvene trditve
Nutrient, substance, food or food category
Vloga – ustrezne določbe Uredbe (ES) št. 1924/2006
Claim
Hranilo, snov, živilo ali kategorija živil
EFSA opinion reference
Trditev
Article 13(5) health claim based on newly developed scientific evidence and/or including a request for the protection of proprietary data.
Referenčno mnenje Agencije za varnost hrane
Citrulline-malate
Zdravstvena trditev po členu 13(5), ki je utemeljena na novih znanstvenih dokazih in/ali vključuje zahtevo za zakonsko zaščito podatkov
Maintenance of ATP levels through reduction of lactates in excess for an improved recovery from muscle fatigue.
citrulin malat
Olive (Olea europaea L.) leaf water extract
Ohranjanje ravni ATP z zmanjšanjem presežka laktatov za boljše okrevanje pri mišični utrujenosti.
Daily intake of supplemental olive leaf extract polyphenols contributes to the reduction of the blood glucose rise after meals.
vodni izvleček iz oljčnih listov (Olea europaea L.)
Pacran® helps to inhibit the adhesion of P-fimbriated E. coli to the urinary tract cells.
Dnevni vnos dodatnih polifenolov v izvlečku iz oljčnih listov prispeva k zmanjšanju dviga glukoze v krvi po jedi.
A combination of Bifidobacterium longum LA 101, Lactobacillus helveticus LA 102, Lactococcus lactis LA 103 and Streptococcus thermophilus LA 104
Pacran® pripomore k inhibiciji adhezije bakterij E. coli s fimbrijami P na celice urinarnega trakta.
Improves intestinal comfort.
kombinacija bakterij Bifidobacterium longum LA 101, Lactobacillus helveticus LA 102, Lactococcus lactis LA 103 in Streptococcus thermophilus LA 104
Regulates your (intestinal) transit.
Izboljša občutek v črevesju.
A combination of L-threonine, L-valine, L-leucine, L-isoleucine, L-lysine plus chromium picolinate
Ureja vaše prehajanje črevesne vsebine.
Contributes to the reduction of the blood glucose rise when consumed together with a carbohydrate rich meal.
kombinacija L-treonina, L-valina, L-levcina, L-izolevcina, L-lizina in kromovega pikolinata
A combination of lutein and zeaxanthin
Prispeva k manjšemu porastu glukoze v krvi, kadar se zaužije skupaj z obrokom, bogatim z ogljikovimi hidrati.
Lutein together with zeaxanthin helps maintain clarity and contrast of sight in bright light conditions.
kombinacija luteina in zeaksantina
Commission Implementing Regulation (EU) 2015/1042
Izvedbena uredba Komisije (EU) 2015/1042
amending Annex II to Regulation (EC) No 250/2009 implementing Regulation (EC) No 295/2008 of the European Parliament and of the Council concerning structural business statistics, as regards the adaptation of the technical format following the revision of the classification of products by activity (CPA)
o spremembi Priloge II k Uredbi (ES) št. 250/2009 o izvajanju Uredbe (ES) št. 295/2008 Evropskega parlamenta in Sveta o strukturni statistiki podjetij glede prilagoditev tehničnega formata po reviziji klasifikacije proizvodov po dejavnosti (CPA)
Having regard to Regulation (EC) No 295/2008 of the European Parliament and of the Council of 11 March 2008 concerning structural business statistics [1], and in particular Article 11(1)(a) thereof,
ob upoštevanju Uredbe (ES) št. 295/2008 Evropskega parlamenta in Sveta z dne 11. marca 2008 o strukturni statistiki podjetij [1] in zlasti člena 11(1)(a) Uredbe,
Regulation (EC) No 295/2008 establishes a common framework for the collection, transmission and evaluation of European statistics on the structure, activity, competitiveness and performance of businesses in the Union.
Uredba (ES) št. 295/2008 vzpostavlja skupni okvir za zbiranje, urejanje, pošiljanje in ocenjevanje evropskih statističnih podatkov o strukturi, dejavnosti, konkurenčnosti ter rezultatih podjetij v Evropski uniji.
Regulation (EC) No 451/2008 of the European Parliament and of the Council [2] establishes a statistical classification of products by activity (CPA), to meet the requirements of statistics in the Union.
Uredba (ES) št. 451/2008 Evropskega parlamenta in Sveta [2] vzpostavlja statistično klasifikacijo proizvodov po dejavnosti (CPA) za zadovoljitev potreb na področju statistike v Uniji.
Annex II to Commission Regulation (EC) No 250/2009 [3] specifies the technical format and the labels for certain products for the data to be transmitted based on the CPA.
Priloga II k Uredbi Komisije (ES) št. 250/2009 [3] določa tehnični format in nazive za nekatere izdelke za podatke, ki jih je treba poslati na podlagi CPA.
Following the entry into force of Commission Regulation (EU) No 1209/2014 [4] it is necessary to adapt Annex II to Regulation (EC) No 250/2009 with regard to the labels for certain products for the data to be transmitted based on the CPA in order to maintain the comparability and consistency with product classification standards used at international level.
Po začetku veljavnosti Uredbe Komisije (EU) št. 1209/2014 [4] je treba prilagoditi Prilogo II k Uredbi (ES) št. 250/2009 glede nazivov za nekatere izdelke za podatke, ki jih je treba poslati na podlagi CPA, da se ohranita primerljivost in skladnost s standardi klasifikacije proizvodov, ki se uporabljajo na mednarodni ravni.
Annex II to Regulation (EC) No 250/2009 should therefore be amended accordingly.
Prilogo II k Uredbi (ES) št. 250/2009 bi bilo zato treba ustrezno spremeniti.
Annex II to Regulation (EC) No 250/2009 is amended in accordance with the Annex to this Regulation.
Priloga II k Uredbi (ES) št. 250/2009 se spremeni v skladu s Prilogo k tej uredbi.
OJ L 97, 9.4.2008, p. 13.
UL L 97, 9.4.2008, str. 13.
Regulation (EC) No 451/2008 of the European Parliament and of the Council of 23 April 2008 establishing a new statistical classification of products by activity (CPA) and repealing Council Regulation (EEC) No 3696/93 (OJ L 145, 4.6.2008, p. 65).
Uredba (ES) št. 451/2008 Evropskega parlamenta in Sveta z dne 23. aprila 2008 o novi statistični klasifikaciji proizvodov po dejavnosti (CPA) in razveljavitvi Uredbe Sveta (EGS) št. 3696/93 (UL L 145, 4.6.2008, str. 65).
Commission Regulation (EC) No 250/2009 of 11 March 2009 implementing Regulation (EC) No 295/2008 of the European Parliament and of the Council as regards the definitions of characteristics, the technical format for the transmission of data, the double reporting requirements for NACE Rev.1.1 and NACE Rev.2 and derogations to be granted for structural business statistics (OJ L 86, 31.3.2009, p. 1).
Uredba Komisije (ES) št. 250/2009 z dne 11. marca 2009 o izvajanju Uredbe (ES) št. 295/2008 Evropskega parlamenta in Sveta glede opredelitev karakteristik, tehničnega formata za prenos podatkov, dvojnih zahtev za poročanje za NACE Rev.
Commission Regulation (EU) No 1209/2014 of 29 October 2014 amending Regulation (EC) No 451/2008 of the European Parliament and of the Council of 23 April 2008 establishing a new statistical classification of products by activity (CPA) and repealing Council Regulation (EEC) No 3696/93 (OJ L 336, 22.11.2014, p. 1).
1.1 in NACE Rev.
Annex II to Regulation (EC) No 250/2009 is amended as follows:
Uredba Komisije (EU) št. 1209/2014 z dne 29. oktobra 2014 o spremembi Uredbe (ES) št. 451/2008 Evropskega parlamenta in Sveta o novi statistični klasifikaciji proizvodov po dejavnosti (CPA) in razveljavitvi Uredbe Sveta (EGS) št. 3696/93 (UL L 336, 22.11.2014, str. 1).
In point 4.2 ‘Territorial unit’, the code ‘GR’ for Greece is replaced by ‘EL’
PRILOGA
In point 4.9 ‘Units of data values’, in the table, a new unit ‘Square metres’ with code ‘M2’ is added.
Priloga II k Uredbi (ES) št. 250/2009 se spremeni:
In point 4.10 ‘Breakdown of products’, the table is amended as follows:
V točki 4.2 „Teritorialna enota“ se oznaka „GR“ za Grčijo nadomesti z „EL“.
for the product with code 63 12 the label ‘Web portal content’ is replaced by ‘Web portal services’.
V točki 4.9 „Enote vrednosti podatka“ se v tabeli doda nova enota „V kvadratnih metrih“ z oznako „M2“.
for the product with code 73 11 13 the label ‘Advertising design and concept development’ is replaced by ‘Advertising concept development services’
V točki 4.10 „Razčlenitev izdelkov“ se tabela spremeni: